Maternal- and/or neonatal-inherited thrombophilia is an important procoagulant risk factor that could lead to the development of obstructive thrombi in the cerebral venous system, and specific thrombophilia mutations, such as a factor V Leiden homozygous mutation, prothrombin gene G20210A mutation, and methylenetetrahydrofolate reductase (MTHFR) 677TT mutation, and protein C, S, and antithrombin III deficiencies are recognized as having a significant effect on thrombotic manifestations [13,15,16]. The gene discussed is F2; the disease is Rare hereditary thrombophilia.